Hutchison MediPharma Partners with Eli Lilly to Advance Development of Fruquintinib in China
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 10 (Table of Contents)
Published: 23 Oct-2013
DOI: 10.3833/pdr.v2013.i10.1985 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Hutchison MediPharma (HMP), the R&D division of the Chinese pharmaceutical and healthcare group Hutchison Chi-Med, has partnered with Eli Lilly for second time with a licensing, co-development and commercialisation agreement for its Phase II cancer drug fruquintinib (HMPL-013), a highly selective small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases with potential in the treatment of advanced refractory solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS